Modeling the immune rheostat of macrophages in the lung in response to infection

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 27, 2009, Pages 11246-11251

  Day, Judy ^a   Friedman, Avner ^a   Schlesinger, Larry S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Alternatively activated macrophages; Lung innate immunity; Mycobacteria tuberculosis

Indexed keywords

CYTOKINE;

ARTICLE; CELL INTERACTION; CELL POPULATION; CELLULAR IMMUNITY; IMMUNOREGULATION; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE; MACROPHAGE ACTIVATION; MATHEMATICAL MODEL; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUBERCULOSIS;

COMPUTER SIMULATION; CYTOKINES; DENDRITIC CELLS; EXTRACELLULAR SPACE; IMMUNE SYSTEM; INTRACELLULAR SPACE; LUNG; MACROPHAGE ACTIVATION; MACROPHAGES, ALVEOLAR; MODELS, IMMUNOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; TIME FACTORS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 67650433616     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0904846106     Document Type: Article

References (57)

1. Valdivia-Arenas MA, Amer A, Henning LN, Wewers MD, Schlesinger LS (2007) Lung infections and innate host defense. Drug Discov Today Dis Mech 4:73-81.
2. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:23-35.
3. Mosser DM(2003) The many faces of macrophage activation. J Leukoc Biol 73:209-212.
4. Martinez FO, Sica A, Mantovani A, Locati M (2008) Macrophage activation and polarization. Front Biosci 13:453-461.
5. Edwards JP, Zhang X, Frauwirth KA, Mosser DM (2006) Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 80:1298-1307.
6. Katakura T, Miyazaki M, Kobayashi M, Herndon DN, Suzuki F (2004) CCL17 and IL-10 as effectors that enable alternatively activated macrophages to inhibit the generation of classically activated macrophages. J Immunol 172:1407-1413.
7. Schebesch C, et al. (1997) Alternatively activated macrophages actively inhibit proliferation of peripheral blood lymphocytes and CD4+ T cells in vitro. Immunology 92:478-486.
8. Stein M, Keshav S, Harris N, Gordon S (1992) Interleukin 4 potently enhances murine macrophage mannose receptor activity: A marker of alternative immunologic macrophage activation. J Exp Med 176:287-292.
9. Fels AO, Cohn ZA (1986) The alveolar macrophage. J Appl Physiol 60:353-369.
10. Fenton MJ, Riley LW, Schlesinger LS (2004) In Tuberculosis and the Tubercle Bacillus, eds Cole ST, Eisenach KD, McMurray DN, Jacobs WR Jr (American Society for Microbiology, Washington, DC), pp 405-426.
11. Flynn JL (2001) Immunology of tuberculosis. Annu Rev Immunol 19:93-129.
12. KaufmannS (2001)Howcan immunology contribute to the control of tuberculosis? Nat Rev Immunol 1:20-30.
13. Gaynor CD, McCormack FX, Voelker DR, McGowan SE, Schlesinger LS (1995) Pulmonary surfactant protein A mediates enhanced phagocytosis of Mycobacterium tuberculosis by a direct interaction with human macrophages. J Immunol 155:5343-5351.
14. Kahnert A, et al. (2006) Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur J Immunol 36:631-647.
15. Verreck, et al. (2004) Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA 101:4560-4565.
16. Rhoades ER, Frank AA, Orme IM(1997) Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. Tuber Lung Dis 78:57-66.
17. Triccas JA, DavenportMP(2008) Infectious diseases: Too little, too late for tuberculosis. Immunol Cell Biol 86:293-294.
18. Marino S, K. D (2004) The human immune response to Mycobacterium tuberculosis in lung and lymph node. J Theor Biol 227:463-486.
19. Friedman A, Turner J, Szomolay B (2008) Amodel on the influence of age on immunity to infection with Mycobacterium tuberculosis. Exp Gerontol 43:275-285.
20. Sud D, Bigbee C, Flynn JL, Kirschner DE (2006) Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J Immunol 176:4296-4314.
21. Wigginton JE, Kirschner D (2001) Amodel to predict cell-mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis. J Immunol 166:1951-1967.
22. Peters W, Ernst JD (2003) Mechanisms of cell recruitment in the immune response to Mycobacterium tuberculosis. Microbes Infect 5:151-158.
23. Dieu MC, et al. (1998) Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med 188:373-386.
24. McWilliam AS, et al. (1996) Dendritic cells are recruited into the airway epithelium during the inflammatory response to a broad spectrum of stimuli. J Exp Med 184:2429-2432.
25. Macatonia SE, et al. (1995) Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells. J Immunol 154:5071-5079.
26. Khader SA, et al. (2006) Interleukin 12p40 is required for dendritic cell migration and T cell priming after Mycobacterium tuberculosis infection. J Exp Med 203:1805-1815.
27. Engele M, et al. (2002) Induction of TNF in human alveolar macrophages as a potential evasion mechanism of virulent Mycobacterium tuberculosis. J Immunol 168:1328-1337.
28. Corinti S, Albanesi C, la Sala A, Pastore S, Girolomoni G (2001) Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 166:4312-4318.
29. Demangel C, Bertolino P, Britton WJ (2002) Autocrine IL-10 impairs dendritic cell (DC)-derived immune responses to mycobacterial infection by suppressing DC trafficking to draining lymph nodes and local IL-12 production. Eur J Immunol 32:994-1002.
30. Giacomini E, et al. (2001) Infection of human macrophages and dendritic cells with Mycobacterium tuberculosis induces a differential cytokine gene expression that modulates T cell response. J Immunol 166:7033-7041.
31. Hickman SP, Chan J, Salgame P (2002) Mycobacterium tuberculosis induces differential cytokine production from dendritic cells and macrophages with divergent effects on naive T cell polarization. J Immunol 168:4636-4642.
32. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A (2001) Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-765.
33. Holt, PG (2000) Antigen presentation in the lung. Am J Respir Crit Care Med 162(4 Pt 2):S151-156.
34. Fenton MJ, et al. (1997) Induction of gamma interferon production in human alveolar macrophages by Mycobacterium tuberculosis. Infect Immun 65:5149-5156.
35. Hirsch CS, Ellner JJ, Russell DG, Rich EA (1994) Complement receptor-mediated uptake and tumor necrosis factor-alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages. J Immunol 152:743-753.
36. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A (1991) IL-10 inhibits cytokine production by activated macrophages. J Immunol 147:3815-3822.
37. Keane J, et al. (1997) Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect Immun 65:298-304.
38. Oddo M, et al. (1998) Fas ligand-induced apoptosis of infected human macrophages reduces the viability of intracellular Mycobacterium tuberculosis. J Immunol 160:5448-5454.
39. Aldwell FE, Wedlock DN, Buddle BM (1997) Sequential activation of alveolar macrophages by IFN-gamma and LPS is required for enhanced growth inhibition of virulent Mycobacterium bovis but not M. bovis BCG. Immunol Cell Biol 75:161-166.
40. Beharka AA, et al. (2005) Pulmonary surfactant protein A up-regulates activity of the mannose receptor, a pattern recognition receptor expressed on human macrophages. J Immunol 169:3565-3573.
41. Steinmüller C, Franke-Ullmann G, Lohmann-Matthes ML, EmmendörfferA(2000) Local activation of nonspecific defense against a respiratory model infection by application of interferon-gamma: Comparison between rat alveolar and interstitial lung macrophages. Am J Respir cell Mol Biol 22:481-490.
42. Xing Z, Zganiacz A, Wang J, Sharma SK (2001) Enhanced protection against fatal mycobacterial infection in SCID beige mice by reshaping innate immunity with IFNgamma transgene. J Immunol 167:375-383.
43. Holt PG, et al. (1993) Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med 177:397-407.
44. Janeway CA, Travers P, Walport M, ShlomchikM(2001) Immunobiology: The Immune System in Health and Disease (Garland, New York), 5th Ed, pp 295-340.
45. Botha T, Ryffel B (2003) Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 171:3110-3118.
46. Flynn JL, et al. (1993) An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 178:2249-2254.
47. Flynn JL, et al. (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561-572.
48. Mohan VP, et al. (2001) Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infect Immun 69:1847-1855.
49. Roach DR, et al. (2002) TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 168:4620-4627.
50. Havlir DV, Barnes PF (1999) Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med 340:367-373.
51. Markowitz N, et al. (1997) Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med 126:123-132.
52. Jones BE, et al. (1993) Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection. Am Rev Respir Dis 148:1292-1297.
53. Marino S, Hogue IB, Ray CJ, Kirschner DE (2008) Amethodology for performing global uncertainty and sensitivity analysis in systems biology. J Theor Biol 254:178-196.
54. Reljic R (2007) IFN-gamma therapy of tuberculosis and related infections. J Interferon Cytokine Res 27:353-364.
55. Rennard SI, et al. (1986) Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60:532-538.
56. Yola A, Sologub T, Nechaev V, Ivanov A (2006) Immune-based therapy using gamma interferon ingaron in the treatment of HIV/AIDS patients with active pulmonary tuberculosis (PTB) not previously highly active antiretroviral therapy (HAART). Retrovirology 3(Suppl 1):S38.
57. Condos R, Rom WN, Schluger NW (1997) Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 349:1513-1515.